The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2022 | Advances & unanswered questions about the role of MRD in AL amyloidosis
Andrew Staron, MD, Boston Medical Centre, Boston, MA, comments on some of the questions surrounding the role of MRD in AL amyloidosis. Whilst MRD seems to have prognostic importance in this disease, assessment timing and frequency remain unclear. In addition, data has suggested that tracking MRD over time may help predict patients at risk of hematologic relapse. However, further studies are required to determine whether providing additional treatment for patients who are MRD-positive is beneficial. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
